Titre:
  • PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: Pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
Auteur:Loibl, Sibylle; Loi, Sherene; Untch, Michael; Conte, PierFranco; Bernards, René; Piccart-Gebhart, Martine; Von Minckwitz, Gunter; Baselga, José; Majewski, Ian IJ; Guarneri, Valentina; Nekljudova, Valentina; Holmes, Eileen; Bria, Emilio; Denkert, Carsten; Schem, Christian; Sotiriou, Christos
Informations sur la publication:Annals of oncology, 27, 8, page (1519-1525)
Statut de publication:Publié, 2016-08
Sujet CREF:Hématologie
Cancérologie
Mots-clés:Double anti-HER2 treatment
HER2+ breast cancer
Neoadjuvant
Pathological complete response
PIK3CA
Survival
Note générale:SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:0923-7534
info:doi/10.1093/annonc/mdw197
info:pii/mdw197
info:scp/84985015825
info:pmid/27177864